Qualitative Study of Suicidal Recrudescence Among Adolescents in November 2021 (Suicide-Covid)

January 26, 2024 updated by: Fondation Lenval

Suicidology and Anthropology Research Protocol : Qualitative Study of Suicidal Recrudescence Among Adolescents in November 2021

A qualitative study, combining psychiatric and anthropological perspectives, focused on the lived experiences of patients who had recourse to HPNCL emergencies during the period of November 2021, as well as the experiences and perceptions of those around them - such as their family, teachers or school and nursing staff. This multi-site approach will provide a multidimensional perspective on the experience of individuals and those around them, as well as a triangulation of data.

The hypotheses to explain the increase in the rate of suicidal crisis will be addressed through semi-structured interviews proposed to the participants of the study.

Study Overview

Detailed Description

Interviews in the presence of two members of the research team (child psychiatrists, psychologists, anthropologists, etc.) will be offered to participants. These interviews will be face-to-face when possible, but can also be done remotely, by teleconsultation, depending on the preferences of the participants.

These interviews will be based on a questionnaire established beforehand evoking the history of mental disorders and the experience of the participant in the study and his entourage of the Covid-19 health crisis.

All information exchanged during these interviews will be made anonymous (data collected and processed as well as the results presented). They will be used exclusively in the context of the study and not communicated to the medical team involved in the patient's care.

The proposed interviews will be carried out separately with:

  • The patient who consulted the emergency room during the month of November 2021
  • The parent(s) of the study participant
  • One or more health professionals taking care of the patient
  • The school attended by the patient who will be questioned about the suicidal problem and Covid-19 in general or not about the patient in particular.
  • Child welfare professionals (ASE) potentially involved in the care of the study participant.

Questionnaires will also be carried out with patients in order to complete the assessment of their clinical condition at a distance from the psychological crisis:

Study Type

Observational

Enrollment (Estimated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

  • The patient who consulted the emergency room during the month of November 2021
  • The parent(s) of the study participant
  • One or more health professionals taking care of the patient
  • The school attended by the patient who will be questioned about the suicidal problem and Covid-19 in general or not about the patient in particular.
  • Child welfare professionals (ASE) potentially involved in the care of the study participant

Description

Inclusion Criteria:

  • Any patient having consulted in the child psychiatric emergency room of the HPNCL between November 1, 2021 and November 30, 2021 for suicidal thoughts.
  • Age between 13 years and 17 years and 11 months
  • Good understanding of written and oral French
  • Collection of the informed consent of the patient and of one of the two parents or holder of parental authority

Exclusion Criteria:

  • Inability to comply with the instructions defined and exposed during inclusion
  • Refusal of participation by the patient or one of the legal guardians

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patents
Questionnaires
Situational Anxiety and Trait Anxiety Inventory
• Beck Depression Inventory scale
Suicidal risk" module of the Mini-International Neuropsychiatric Interview child/adolescent version
Post-traumatic Check List Scale

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Situational Anxiety and Trait Anxiety Inventory
Time Frame: at inclusion

This inventory aims to assess anxiety as a "personality trait" (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' "emotional state" linked to a particular situation (feelings of apprehension, tension or nervousness that the subject feels at a specific moment).

This is a questionnaire comprising 20 items for the "state" form and 20 items for the "trait" form. The instruction is to answer "in general, in the usual way" for the "trait" scale and "at the moment" for the "state" scale.

Each score can therefore vary from 20 to 80 with a "very high" anxiety norm when the threshold is > 65, "high" between 56 and 65, "medium" between 46 and 55, "low" between 36 and 45 and "very low" for a score < or = 35.

at inclusion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Beck Depression Inventory
Time Frame: at inclusion
The Beck Depression Inventory is a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents. It consists of 21 symptom and attitude items, which describe a specific behavioral manifestation of depression, graded from zero to three by a series of four statements reflecting the degree of severity of the symptom. The subject must indicate, among the propositions, the one that best describes how he has felt during the last seven days. The total score varies between 0 (absence of depressive symptoms) and 63. Some authors suggest that in a normal population, a total BDI score greater than 15 is an argument in favor of depression. The results of this scale can also be categorized according to: normal score < 15; mild depression: 10 to 18; moderate depression: 19 to 29; severe depression > 30
at inclusion
"Suicidal risk" module of the Mini-International Neuropsychiatric Interview child/adolescent
Time Frame: at inclusion
The MINI is a short structured diagnostic interview, jointly developed by psychiatrists and clinicians in the United States and Europe, for DSM IV and CIM 10 psychiatric disorders. It was designed to meet the need for a short structured psychiatric interview for clinical trials and epidemiological studies and for use as a first step in monitoring outcomes in clinical settings. Its very brief "suicide risk" module is sometimes used alone to determine the level of suicide risk. It is composed of 6 binary questions. The level of risk is established according to the number of questions having obtained a positive answer
at inclusion
Post-traumatic Check List Scale
Time Frame: at inclusion
The questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month. The maximum score is 80. A threshold of 33 to 38 is proposed for screening for post-traumatic stress disorder (PTSD)
at inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Louise-Emilie DUMAS, MD, Fondation Lenval

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 12, 2022

Primary Completion (Estimated)

March 1, 2024

Study Completion (Estimated)

March 1, 2024

Study Registration Dates

First Submitted

March 21, 2023

First Submitted That Met QC Criteria

March 21, 2023

First Posted (Actual)

April 3, 2023

Study Record Updates

Last Update Posted (Actual)

January 29, 2024

Last Update Submitted That Met QC Criteria

January 26, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 22-HPNCL-07

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on STAI-Y

3
Subscribe